Timely recommendation for drug reimbursement by health technology assessment (HTA) agencies is critical to ensure patient access to medicines of therapeutic value. As part of an ongoing study to monitor regulatory and HTA performance, CIRS collected data on new active substances (NASs) appraised in 2014 and 2015 by eight HTA agencies, analysingsynchronisationbetween the regulatory decision and first HTA recommendation in timing and outcome.
Recommendations were collected from the Australian Pharmaceutical Benefits Advisory Committee (PBAC), Canadian Agency for Drugs and Technologies in Health (CADTH), British National Institute for Health and Care Excellence (NICE), French Haute Autoritéde Santé(HAS), German Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG), Polish Agencja Oceny Technologii Medycznych i Taryfikacji (AOTMiT), Scottish Medicines Consortium (SMC) and Swedish Tandvårds-& läkemedelsförmånsverket(TLV), for products approved between 2012-2015 by the respective jurisdictional regulatory agencies, the Australian Therapeutic Goods Administration (TGA), Health Canada and European Medicines Association (EMA).